New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 26, 2014
07:46 EDTIPXL, AVNRAvanir likely win patent case against Impax, says Jefferies
After reviewing court transcripts, Jefferies believes Avanir (AVNR) is likely to win its Nuedexta patent trial against Impax (IPXL). The firm says that while the stock is may rally on the patent win, it sees limited upside and keeps a Hold rating on Avanir. Jefferies notes that its $4 price target already assumes full credit for the Nuedexta patent.
News For AVNR;IPXL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 20, 2015
07:18 EDTAVNR, IPXLAmerican Academy of Neurology to hold annual meeting
Subscribe for More Information
April 17, 2015
10:00 EDTIPXLOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
05:58 EDTIPXLImpax downgraded to Sell from Neutral at UBS
UBS downgraded Impax Laboratories to Sell saying the risk/reward is biased to the downside following the recent rally in shares. UBS attributes the recent run-up in shares to expectations the company will do more deals or get acquired. The firm does not see either scenario driving the stock much above current levels "any time soon." It keeps a $36 price target for Impax shares.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use